Rituximab-induced regression of CREST-related calcinosis

被引：0
作者：
Dayane Raquel de Paula
Fabiane Barbero Klem
Pedro Gabriel Lorencetti
Carolina Muller
Valderilio Feijó Azevedo
机构：
[1] Federal University of Paraná,Faculty of Medicine
[2] Federal University of Paraná,Scleroderma Outpatient Clinic, Hospital de Clinicas
[3] Federal University of Paraná,Hospital de Clinicas
[4] Edumed-Health Research and Education,undefined
来源：
Clinical Rheumatology | 2013年 / 32卷
关键词：
Calcinosis; Rituximab; Scleroderma; Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
About a quarter of sclerodermic patients present calcinosis. However, patients with limited form of the disease are more likely to have calcinosis than patients with diffuse form. We report a case of a 54-year-old female patient with limited cutaneous scleroderma using rituximab (RTX) to treat lung fibrosis and arthritis. Into RTX treatment, she also had a complete resolution of calcinosis in her hands. The patient reported improvement in dyspnea and synovitis after two courses of RTX (four weekly infusions 375 mg/m2 each). After 7 months of the first infusion, the calcinosis in her fingers had a complete remission, especially the right thumb. Based on current evidences, we discuss the use of rituximab as a promising therapy to treat not only lung disease but also calcinosis in patients with scleroderma.
引用
收藏
页码：281 / 283
页数：2
相关论文
共 74 条
[1]  
Robertson LP(2003)Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline Ann Rheum Dis 62 267-269
[2]  
Marshall RW(2005)Calcinosis in rheumatic diseases Semin Arthritis Rheum 34 805-812
[3]  
Hickling P(2011)Calcinosis cutis: part II. Treatment options J Am Acad Dermatol 65 15-22
[4]  
Boulman N(2010)Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate Joint Bone Spine 77 70-72
[5]  
Slobodin G(2012)Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature Semin Arthritis Rheum 41 822-829
[6]  
Rozenbaum M(2011)Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids Ther Adv Respir Dis 5 299-304
[7]  
Rosner I(2010)Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study Rheumatology (Oxford) 49 271-280
[8]  
Reiter N(2008)Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab Rheumatology (Oxford) 47 552-553
[9]  
El-Shabrawi L(2006)Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 354 2655-2666
[10]  
Leinweber B(2011)B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence Int J Rheumatol 2011 7-583
12345678